All In Biotech

Drug Trial Radar · NCT07669779

A Phase II Study of AK146D1 in Combination With AK112 in Advanced Non-Small Cell Lung Cancer

A Phase II Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics and Antitumor Efficacy of AK146D1 in Combination With AK112 or Other Anticancer Therapies in Patients With Advanced Non-Small Cell Lung Cancer

Last checked: Nov 19, 2026Latest source record: Jul 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

348

Planned (sponsor's estimate)

Start

Jul 10, 2026

Primary completion

Aug 30, 2027

Study completion May 30, 2029

Sponsor

Lead sponsor
AkesoIndustry
Sponsor type
Industry
First posted
Jun 25, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase II clinical study evaluating the safety, tolerability, pharmacokinetics and antitumor efficacy of AK146D1 in combination with AK112 or other anticancer therapies in patients with advanced Non-Small Cell Lung Cancer.

Conditions

  • Advanced Non Small Cell Lung Cancer (NSCLC)

Interventions

  • AK146D1 for injectionDrug

    AK146D1 for injection is an anti-Trop2/Nectin4 bispecific antibody-drug conjugate.

  • AK112 InjectionDrug

    AK112 is a PD-1/VEGF bispecific antibody.

  • Platinum chemotherapyDrug

    Carboplatin or cisplatin will be administered.

  • OsimertinibDrug

    Osimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with dose limiting toxicities (DLTs)Time frame: During the first 3 weeks of treatment in Safety Run-in Phase.
  2. Number of participants with adverse events (AEs)Time frame: From the time of signing informed consent form through 30 days(for AEs) or 90 days(for SAEs) after the last dose of study drug.
  3. Objective Response Rate (ORR) assessed by investigator per RECIST v1.1Time frame: Up to approximately 2 years.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • SunYat-sen University Cancer Center

    Guangzhou, Guangdong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.